Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

PRDX4-enriched exosomes from adipose stem cells enhance diabetic wound repair through angiogenic activation.

Chen X., Jiang Y., Tao Y., Zhang W., Zhuo H., Sun Y.

Animal Study on Diabetic Foot, Chronic Wound, published in Burns (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Burns (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
42296599
DOI
10.1016/j.burns.2026.108061

Abstract (original English)

Background Diabetic (DM) wounds are a major challenge in dermatology. Despite the therapeutic effectiveness of stem cell therapy in wound repair, clinical applications remain limited. We investigated whether adipose-derived exosomes (Exos) can promote healing in diabetic mice. Methods High-throughput sequencing (HTS) was employed to study abnormal circular RNA expression in ulcerated tissue with or without adipose-derived stem cell (ADSC)-Exo treatment. EPCs were employed to analyze reactive oxygen species (ROS), apoptosis, and angiogenic differentiation functions. A DM ulceration mouse model was generated and Exo therapeutic effects were investigated. Results Data demonstrated that ADSC-Exo treatment enhances wound healing (WH) of diabetic mice through inhibiting ROS deposition and restoring angiogenic function under high glucose (HG) conditions. The HTS in the current research revealed that ADSC-Exo treatment resulted in altered gene expression, including of peroxiredoxin 4 (PRDX4). PRDX4 downregulation inhibited the Exo protective effects on WH. PRDX4 overexpression inhibited HG-induced EPC dysfunction and augmented Exo therapeutic effects on WH. Conclusion Our data indicated that Exos derived from ADSCs promoted diabetic wound (DW) healing through delivering PRDX4 and improving endothelial cell function, which aids in the development of stem cell-based therapeutic treatment

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research